A smartphone app to improve social thinking in people with schizophrenia
Tests the AffectUs smartphone app for social cognition in people with schizophrenia.
Plain-language title generated from the registry record
Registry title: Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 60 years old?
Source: NCT07755605, who can take part
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT07755605
- Record updated
- 21 August 2026
- Original description
The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue perception, in individuals with schizophrenia spectrum disorders.Read full original descriptionShow less
A Prospective, Randomized Parallel, Single Institution, Researcher-led Clinical Trial on the Effect of Improving Social Cognitive Function by Using Digital Therapy Devices in Patients With Schizophrenia Spectrum Disorder
The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue perception, in individuals with schizophrenia spectrum disorders.
In this randomized controlled trial, participants will be assigned either to use AffectUs for 10 weeks in addition to treatment as usual or to receive psychoeducational materials and treatment as usual. Participants will complete assessments at baseline, week 5, week 10, and week 15 to evaluate social cognition, clinical outcomes, and safety.
Exclusion: Initiation of or current participation in structured psychosocial interventions (e.g., cognitive behavioral therapy or social cognition training) within the past 3 months; Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data interpretation; Current or past diagnosis of intellectual disability; Considered by the investigator to be at significant risk of suicide. 4, Pregnant or having a positive pregnancy test at screening.
Inclusion Criteria; Participants must meet all of the following criteria:; Adults aged 19 to 60 years; Meet the diagnostic criteria for schizophrenia or schizoaffective disorder according to DSM-5 and ICD-11; Have completed at least a middle school education; Be able to read and write in Korean; Be able to use a smartphone application independently; Provide written informed consent before participation; Receiving stable antipsychotic treatment (dose variation ≤30%) for at least 3 months before enrollment.